An excipient is a pharmacologically inactive substance formulated alongside the active pharmaceutical ingredient of a medication. The pharmaceutical industry always tries to satisfy patient’s therapeutical needs and apart from active ingredients, inactive excipients play a major role in formulation development.
Global Binder Excipients Market: Overview
- An excipient is a pharmacologically inactive substance formulated alongside the active pharmaceutical ingredient of a medication. The pharmaceutical industry always tries to satisfy patient’s therapeutical needs and apart from active ingredients, inactive excipients play a major role in formulation development. Binder excipients are formulated to act as an adhesive to literally bind together powders, granules, and other dry ingredients to provide necessary mechanical strength. In other words, binders are essential to achieve the hardness of the tablet. Binders are usually selected on the basis of product needs and vendor preference. The primary criterion when choosing a binder is its compatibility with other tablet components.
- The global binder excipients market is projected to expand at a significant pace during the forecast period, owing to rise in uses in various pharmaceutical products
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75951
Key Drivers of Global Binder Excipients Market
- Increase in demand for various pharmaceutical products on account of aging population and rising cases of chronic diseases act as the major factor driving the binder excipients market worldwide. Moreover, rise in demand for excipients with more functionality is further projected to fuel the requirement for binder excipients in drug manufacturing companies.
- Rise in number of clinical trials of new drugs is likely to drive the demand for binder excipients
Market Restraints
- Lack of separate guidelines for manufacturing and approval of excipients is deterring R&D initiatives related to novel binder excipients. Under the present regulatory scenario, if a new drug approval fails, the excipient also fails even if it is not due to anything related to the excipient. Furthermore, clinical trial data from that failed excipient is not usable. This leads to major financial loss on the part of both the drug and the excipient manufacturer.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=75951
Asia Pacific to Hold Major Share of Global Binder Excipients Market
- Asia Pacific is likely to dominate the global binder excipients market due to increase in requirement of binder excipients in the local drug manufacturing industry for generic drugs business. Generic drug producers in countries such as India hold a strong position in the global market and play an integral role in developing the pharmaceutical industry which also created a strong demand for binder excipients for generic drugs. At present, pharmaceutical companies in India supply over 80% of the anti-retro-viral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome). In 2017–2018, India exported about US$ 3.2 Bn worth of generic drugs to the U.S.
Pre Book Binder Excipients Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=75951<ype=S
Key Players Operating in Global Market
Major players operating in the global binder excipients market are:
- BASF SE
- Lonza Group
- BENEO
- DFE Pharma
- Kerry Inc.
- DuPont de Nemours, Inc.
- JRS PHARMA
- Ashland
- BPSI Holdings LLC.
More Trending Reports by Transparency Market Research:
Food Intolerance Testing Market: Food intolerance is an abnormal non-immune response with allergy-like symptoms after ingesting of food. It can result from pharmacological reactions, enzyme deficiencies, or response to toxic or irritant components of food. Symptoms of food intolerance include irritable bowel syndrome (IBS), urticaria, skin rashes, nasal congestion, angioedema and eczema, pharyngeal irritations, sinusitis, asthma and unproductive cough, abdominal cramp, mouth ulcers, intermittent diarrhea, nausea, gas, and constipation.
Triclabendazole Market: Triclabendazole was first used to treat Fasciola hepatica infections in animals in the early 1980s. It has established itself as the primary anti-fluke medication on the market due to its strong action against immature flukes. Triclobendazole has recently been used to treat human cases of fascioliasis; and currently, it is the treatment of choice for this infection as well.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/